US008901171B2

(12) **United States Patent**
Kitamoto

(10) **Patent No.: US 8,901,171 B2**
(45) **Date of Patent: Dec. 2, 2014**

(54) **COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT**

(71) Applicant: **Takeda Pharmaceutical Company Limited**, Osaka (JP)

(72) Inventor: **Naomi Kitamoto**, Kanagawa (JP)

(73) Assignee: **Takeda Pharmaceutical Company Limited**, Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/971,159**

(22) Filed: **Aug. 20, 2013**

(65) **Prior Publication Data**

US 2013/0345304 A1 Dec. 26, 2013

Related U.S. Application Data

(63) Continuation of application No. 13/574,848, filed as application No. PCT/JP2011/052077 on Jan. 26, 2011.

(30) **Foreign Application Priority Data**

Jan. 27, 2010 (JP) 2010-015935

(51) **Int. Cl.**

C07C 311/28	(2006.01)
A61K 31/69	(2006.01)
A61K 31/4545	(2006.01)
A61K 31/428	(2006.01)
A61K 31/4192	(2006.01)
A61K 31/282	(2006.01)
A61K 31/337	(2006.01)
A61K 31/4196	(2006.01)
A61K 31/41	(2006.01)
A61K 31/216	(2006.01)

(52) **U.S. Cl.**

CPC ***C07C 311/28*** (2013.01); ***A61K 31/69*** (2013.01); ***A61K 31/4545*** (2013.01); ***A61K 31/428*** (2013.01); ***A61K 31/4192*** (2013.01); ***A61K 31/282*** (2013.01); ***A61K 31/337*** (2013.01); ***A61K 31/4196*** (2013.01); ***A61K 31/41*** (2013.01); ***A61K 31/216*** (2013.01)

USPC **514/529**

(58) **Field of Classification Search**

USPC 514/529

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,769,372	A	9/1988	Kreek
4,785,000	A	11/1988	Kreek et al.
5,053,419	A	10/1991	Lipton
5,059,712	A	10/1991	Griffith
5,158,883	A	10/1992	Griffith
5,234,956	A	8/1993	Lipton
5,334,618	A	8/1994	Lipton
5,455,279	A	10/1995	Lipton
5,506,231	A	4/1996	Lipton
5,614,560	A	3/1997	Lipton
5,747,545	A	5/1998	Lipton
5,801,203	A	9/1998	Lipton
5,804,374	A	9/1998	Baltimore et al.
6,071,876	A	6/2000	Lipton et al.
6,150,090	A	11/2000	Baltimore et al.
6,410,516	B1	6/2002	Baltimore et al.
6,495,604	B1	12/2002	Ichimori et al.
6,511,800	B1	1/2003	Singh
7,078,540	B1	7/2006	Tamura et al.
7,271,248	B2	9/2007	Hardiman et al.
7,417,059	B2	8/2008	Tamura et al.
7,670,603	B2	3/2010	Hardiman et al.
7,863,263	B2	1/2011	Ohmoto et al.
2002/0052019	A1	5/2002	Goddard et al.
2002/0055173	A1	5/2002	Parks et al.
2002/0086368	A1	7/2002	Gurney
2003/0032090	A1	2/2003	Hardiman et al.
2003/0087387	A1	5/2003	Gurney
2003/0195256	A1	10/2003	Singh
2003/0212114	A1	11/2003	Sato
2004/0049041	A1	3/2004	Ikemoto et al.
2004/0063685	A1	4/2004	Itzawa et al.
2004/0072138	A1	4/2004	Singh
2004/0171086	A1	9/2004	Fink et al.
2004/0191833	A1	9/2004	Fink et al.
2004/0214757	A1	10/2004	Baltimore et al.
2004/0253276	A1	12/2004	Sato et al.
2004/0259790	A1	12/2004	Pulendran et al.
2005/0059072	A1	3/2005	Birmachu et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	1 063 228	A1	12/2000
EP	1 209 149	A1	5/2002

(Continued)

OTHER PUBLICATIONS

Joseph (Oxaliplatin Acts on IB-4-Postive Nociceptors to induce an Oxidative Stress-Dependent Acute Painful Peripheral Neuropathy, The Journal of Pain, vol. 9, No. 5, 2008 pp. 463-472).*

Bettoni et al., "Glial TLR4 Receptor as New Target to Treat Neuropathic Pain: Efficacy of a New Receptor Antagonist in a Model of Peripheral Nerve Injury in Mice," GLIA, Sep. 2008, 56(12)1 312-1319.

Fairman et al., "Blockade of Stimulated Rat Microglial, Macrophage and Human Peripheral Blood Mononuclear Cell (PBMC) Toll-Like Receptor 4 (TLR4), Significantly and Completely Reverses Proinflammatory Cytokine Release, Potential Therapeutic Target for Inflammatory & Neuropathic Pain," 13th World Congress on Pain, Abstract of Presentation No. PW 140, presented Sep. 1, 2010, abstract published Jun. 4. 2010, 2 pages.

(Continued)

Primary Examiner — San-Ming Hui
Assistant Examiner — Kathrien Cruz
(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(57) **ABSTRACT**

The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.

9 Claims, No Drawings